Novo Nordisk A/S: Transaction in Own Shares | Company Announcements

Monday 02 November, 2009

Novo Nordisk A/S

Transaction in Own Shares



Novo Nordisk A/S - Share repurchase programme


On 7 August 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an
amount up to DKK 2.4 billion in the period from 10 August 2009 to 18
December 2009.

Since the announcement as of 26 October 2009, the following
transactions have been made under the programme:


                  Number of    Average     Transaction value,
                   shares   purchase price        DKK
Accumulated, last
announcement      4,222,050                     1,347,733,822
26 October 2009      52,950       323.8990         17,150,452
27 October 2009      77,500       324.4390         25,144,023
28 October 2009      75,000       327.1799         24,538,493
29 October 2009     151,599       314.7490         47,715,634
30 October 2009      90,000       313.7299         28,235,691
Accumulated under
 the programme    4,669,099                     1,490,518,113


Transactions related to Novo Nordisk's incentive programmes have
resulted in a net sale by Novo Nordisk of 29,080 B shares in the
period from 29 October 2009 to 30 October 2009. The shares in these
transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of
29,476,827 treasury shares, corresponding to 4.8% of the share
capital. The total amount of shares in the company is 620,000,000
including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,000
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.

Further information:

Media:                 Investors:

Mette Kruse Danielsen  Mads Veggerby Lausten
Tel: (+45) 4442 3883   Tel: (+45) 4443 7919
mkd@novonordisk.com    mlau@novonordisk.com

                       Kasper Roseeuw Poulsen
                       Tel: (+45) 4442 4471
                       krop@novonordisk.com

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   hrmm@novonordisk.com



 Company Announcement no 65 / 2009




http://hugin.info/2013/R/1351981/326923.pdf


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.

Investegate takes no responsibility for the accuracy of the information within the site.

The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.